^
    Back
    Association details:
    Biomarker:KIT mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:adavosertib (AZD1775) (WEE1 inhibitor) +
    Ayvakit (avapritinib) (CSF-1R inhibitor, PDGFR antagonist, mutant c-KIT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    JCI Insight
    Title:

    Identification of Wee1 as target in combination with avapritinib for Gastrointestinal Stromal Tumor treatment

    Published date:
    12/15/2020
    Excerpt:
    In vitro and in vivo studies revealed significant efficacy of MK-1775 (Wee1 inhibitor) in combination with avapritinib in KIT and PDGFRA-mutant GIST cell lines...
    DOI:
    10.1172/jci.insight.143474